WDA (Wholesale Distribution Authorisation)
ProPharma can assisst with obtaining MHRA WDA Licence
Our WDA Expertise
ProPharma is a leader in assisting clients to navigate the complex landscape of Wholesale Distribution Authorisation (WDA) requirements. Our expertise encompasses the full spectrum of services needed to obtain and maintain a WDA, ensuring compliance with the stringent regulations set by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Veterinary Medicines Directorate (VMD). We provide comprehensive support, including writing and refining Quality Management Systems (QMS), conducting thorough gap analyses, and performing vendor audits. Our team of experienced professionals delivers tailored training programs for employees and conducts mock inspections to prepare clients for regulatory reviews. With our robust understanding of Good Distribution Practice (GDP) principles and guidelines, ProPharma ensures that our clients meet all the necessary standards to achieve and sustain their WDA status.
ProPharma's Experience with WDA Applications
ProPharma has a proven track record of successfully guiding clients through the WDA application process and beyond. Our extensive experience includes supporting clients in applying for both human and veterinary WDA licenses, providing contract Responsible Persons (RP), Responsible Person import (RPi), and Wholesale Qualified Persons (WQP). We can also provide contract Qualified Person (QP) support to our clients either on their Manufacturers Import Authorisation (MIA) or under ProPharma’s MIAs. We have developed and implemented numerous Quality Management Systems (QMS) tailored to our clients' specific needs, ensuring compliance and readiness for regulatory inspections. Our team has fronted regulatory inspections on behalf of clients, delivering post-inspection remedial support to address any issues identified. With a commitment to excellence, ProPharma's experienced professionals have consistently enabled clients to achieve their WDA goals, maintaining the highest standards of quality and compliance.
What is a WDA (Wholesale Distribution Authorisation)?
A wholesale distribution authorisation (WDA) is a legal requirement for any company that stores or distributes human or veterinary medicines in the UK. A WDA is also known as a “wholesale dealer licence” or a “wholesale dealer authorisation”, and it replaces the previous term of wholesale dealers’ licence (often called WDL or WL).
There are different types of WDA available depending on the nature and scope of the distribution activities.
A WDA can cover both licensed and unlicensed medicines, as well as investigational medicinal products (IMPs) for use in clinical trials, depending on the scope applied for in the application.
For example, a WDA (H) is for medicines for human use, a WDA (V) is for medicines for veterinary use, and a WDA (IMP) is for investigational medicinal products.
WDA (H) and (V)
A WDA (H) is issued by the Medicines and Healthcare products Regulatory Agency (MHRA), which is the UK authority responsible for ensuring the quality, safety, and efficacy of human medicines.
A WDA (V) is issued by the Veterinary Medicines Directorate, which is the UK authority responsible for ensuring the quality, safety, and efficacy of veterinary medicines.
WDAs will vary as to the specific conditions or restrictions attached to them, such as
- activities covered – procurement, holding, supply, export, other activities
- products with additional requirements – medical gases, cold chain, narcotic or psychotropic products, products derived from blood, immunological products, radiopharmaceuticals.
- legal category of products - prescription only medicine (POM) pharmacy sale (P), general sales list (GSL), controlled drugs (CD) which also require the appropriate Home Office licence issued under the Misuse of Drugs Regulations 2001, Traditional Herbal medicinal Products (THMP), Homeopathic products.
- source of products - UK, EU or non-UK/EU manufactured.
- destination of products – UK domestic market, or export to EU or non -EU countries.
Who needs a WDA?
Anyone who procures, stores, or supplies medicines to anyone other than the patient using the medicine needs a WDA (H), and for veterinary products a WDA (V). This includes wholesalers, distributors, importers and exporters.
Online retailers of medicines do not require a wholesale authorisation if they are supplying the end user in quantities of less than 3 months’ supply. Brokers required a broker registration, which permits negotiation on trades, but not the ability to buy, sell or hold.
Requirements prior to applying for a WDA (H) or WDA (V)
Prior to applying for a WDA (H) application, one needs to demonstrate compliance with the Human Medicines Regulations (2012), GDP principles and guidelines which cover the quality system, personnel, premises and equipment, documentation, operations, complaints, recalls, returns, falsified medicines, outsourced activities, self-inspections, transportation, and brokers.
These requirements are addressed in the 10 Chapters of the EU GDP Guidelines (2013/C 343/01).
To apply for a WDA (H), one needs to complete an online application form and submit it to the MHRA, along with the required accompanying documents and fees.
The MHRA will conduct a GDP inspection of the site within 90 days of a validated application before granting or renewing a licence and will also conduct periodic risk-based inspections to monitor ongoing compliance.
The process for applying for a WDA (V) is similar to that for a WDA (H), except that the application and inspection is via the Veterinary Medicines Directorate (VMD).
Responsibilities of a WDA holder
The WDA holder has a number of responsibilities and obligations to ensure the compliance with the GDP standards and the WDA conditions. Some of these include:
- Implementing and maintaining a quality management system (QMS) that meets the GDP requirements
- Appointing a responsible person (RP) for GDP for a WDA (H) or a wholesale dealer qualified person (WQP) for a WDA (V), who oversees and ensures the compliance with the GDP principles and guidelines. The exact requirements for an RP/WQP are set in the national legislation, but in general, it is a degree in Natural Science/Pharmacy and relevant experience in GDP is required.
- Following Brexit in January 2020 a new role of Responsible Person import (RPi) was introduced to oversee the certification of imported EU Qualified Person certified UK stock into the UK under a WDA (H).
- Ensuring that the personnel involved in the distribution activities are adequately trained and competent
- Verifying the authenticity and quality of the products before they are procured, stored, or supplied
- Managing the risks associated with the distribution activities, such as deviations, complaints, recalls, and falsified medicines
- Conducting self-inspections and audits of the suppliers and customers
- Ensure that all storage warehouses and transportation vehicles are temperature mapped
- Ensure that all storage warehouses have adequate security, are clean and free from contamination, designated areas for receipt of medicines, appropriate temperature-controlled areas such as ambient, fridges, freezers, and appropriate pest controls in place
- Keeping accurate and up-to-date records of all the distribution activities
- Have proper stock rotation and carry out a detailed stock audit at least once a year
- Store and transport medicines in line with each products storage and transportations conditions as listed in the Marketing Authorisation (MA)
- Cooperating with the MHRA/VMD and providing them with the necessary information and documentation
- Reporting any suspected adverse reactions or quality defects to the MHRA/VMD
- Have an emergency recall plan; a system in place that if a recall of the product is required then the company is readily able to identify and contact all their customers
- Notifying the MHRA/VMD of any changes to the WDA (H)/WDA (V) details or activities
- Renewing the licence every five years
How can ProPharma assist you in obtaining a WDA?
PropPharma has assisted many clients to obtain their own WDA (H) and WDA (V) including the following activities:
- writing their Quality Management System (QMS)
- conducting a gap analysis on their current QMS and undertaking remediation support
- auditing their vendors
- GDP training of employees
- undertaking mock inspections and recalls
- applying for their WDA licenses
- providing contract Responsible Person’s (RP), responsible Person import (RPi) and contract Wholesale Qualified Person’s (WQP)
- providing contract quality managers
- fronting the regulatory inspection for the client
- providing post inspection remedial support
ProPharma has extensive experience in developing Quality Management Systems (QMS) to support clients to apply for their own WDA (H) or WDA (V) and overseeing their regulatory inspection.
We have registered Qualified Persons and Responsible Persons who are eligible to act a RP, RPi or WQP on our clients’ WDA (H) or WDA (V).
ProPharma WDA Licence Assistance
If you need help obtaining a WDA, connect with our experts today. We are here to discuss your current issues and concerns and provide you with a bespoke solution.
WDA Experts
-
David Crome
Managing Director, Quality & Compliance UK & India
View Bio
-
Alexis O’temro
Associate Director, Quality & Compliance
-
Ruth Buchanan
Associate Director, Quality & Compliance
View Bio
-
Saket Jadhav
Quality Assurance Consultant
View Bio
David Crome
With over 45 years of experience in the pharmaceutical industry, David Crome has worked with both branded and generic multinational companies, including a decade in consultancy. His career has spanned most functions in the industry, covering the entire product lifecycle: R&D, regulatory, production, QA, supply chain, auditing (with over 150 audits undertaken), marketing, setting up new businesses, and assisting clients in attaining EU/UK GMP certification. David has participated in over 60 regulatory inspections conducted by various agencies, such as the MHRA, HPRA, EMA, SUKL, USFDA, SAHPRA, and Anvisa, across England, Ireland, Argentina, Bangladesh, the Czech Republic, and India.
Alexis O’temro
Ruth Buchanan
Ruth Buchanan has over 28 years of experience in the pharmaceutical industry, working with both branded multinationals and small generic manufacturing and virtual pharmaceutical companies, including six years in consultancy. She has worked within the technical and quality functions of the industry, focusing on solid dose, respiratory, creams, and liquids, with human and veterinary medicines. Her expertise includes product transfer, auditing, and assisting clients in attaining EU/UK GMP certification. Ruth has been named as a Qualified Person, Responsible Person, and Responsible Person (Import). She has experience hosting and leading regulatory inspections by agencies such as the MHRA, VMD, and FDA for both existing and new manufacturing licenses and WDA(H).
Saket Jadhav
Saket Jadhav has over 13 years of experience in the pharmaceutical industry, working in both regulatory and quality functions, including five years in consultancy. He has been involved in technical and quality roles covering solid dose and parallel import, technology transfer, auditing, and assisting clients in obtaining WDA(H) approval. Saket has also served as a Responsible Person and Responsible Person (Import). He has successfully hosted MHRA audits for both new and existing MIA and WDA(H) licenses.
News & Insights
December 19, 2024
WHO Issues Guidance on Antibiotic Pollution Control
WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.
December 18, 2024
Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding
Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.
October 21, 2024
ProPharma Appoints Brian Tuttle as Chief Financial Officer
ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
September 24, 2024
ProPharma Honored in the 2024 Clinical Trials Excellence Awards
ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.
June 10, 2022
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
August 31, 2022
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
News & Insights
December 18, 2024
Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding
Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.